The Four Guidances of the Apocalypse | GenomeWeb

The US Food and Drug Administration's recently released guidance on pharmacogenomic data submissions is an important step in the FDA's evolving ability to obtain, analyze, and, ultimately, approve pharmacogenomics data in drug discovery and development.

The guidance, whose release has been delayed several times since it was unveiled as a draft in November 2003, is actually one of four pharmacogenomics-related guidance documents that the FDA has in various stages of development.

The other three are:

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.